Shareholders of biotech company look past quarterly numbers to pending release of interim results on Provenge.
Results 1 - 5 of 5 for "DENDREON"
The biotech's shares remain stagnant as investors wait for key prostate cancer treatment data in the fall.
The biotech's shares barely move as investors await the results of its prostate cancer treatment study.
Today’s tickers: IBB, DNDN, SQNM, HGSI, MOT, GRA, IP, CDE, EMC, HOLX IBB, - News of Bristol-Myers Squibb’s bid to acquire ImClone excited traders about the many and varied possible M&A configurations in the sector (and helped the sector shake off yesterday’s killjoy Alzheimer’s drug data from Elan and Wyeth). Shares in the iShares Nasdaq Biotech Index – which numbers biotech heavies Amgen, ...
Today’s tickers: IBB, DNDN, SQNM, HGSI, MOT, GRA, IP, CDE, EMC, HOLX IBB, - News of Bristol-Myers Squibb’s bid to acquire ImClone excited traders about the many and varied possible M&A configurations in the sector (and helped the sector shake off yesterday’s killjoy Alzheimer’s drug data from Elan and Wyeth). Shares in the iShares Nasdaq Biotech Index – which n...